AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

European shares surged, fueled by a ceasefire agreement between Iran and Israel brokered by U.S. President Trump, boosting ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca Pharma India, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹8883. The stock has experienced fluctuations today ...